Developing therapies against different aging related diseases.
Juvenescence is a bio-pharma development company developing therapies focused on allowing people worldwide to live longer, healthier lives. We have raised USD $65M to build an ecosystem and pipeline of assets targeting ageing, age-related disease and regeneration.
Visit website: https://www.juvlabs.com/
Juvenescence is also referenced in the following:
Developing preventative medicines for age-related disease using ketone bodies
Executive Director of Juvenescence’s JuvTherapeutics Division
Focused on a novel target linked to one of the fundamental processes of aging
Company focused on novel ketone-based therapies for the treatment of heart diseases
Juvenescence webinar about the latest research and developments on future of longevity investment
People at Juvenescence
Chief Operating Officer and CEO of Therapeutics Division at Juvenescence
CEO at Juvenescence Life.
Chief Executive Officer of the Epigenetics Division of Juvenescence Limited
CEO at Juvenescence and chairman of Portage Biotech, Inc.
JuvLife Division raises 3.7 million euros for making antiaging product with Chrysea
Longevity Technology - 13-Jun-2022
Metabolites induce autophagy, stimulate cellular regeneration for healthy ageingRead more...
Selah Therapeutics launched to focus on ketone-based therapies for heart disease
Longevity Technology - 13-May-2022
Treatment options for diseases of aging - from the makers of metabolic switchRead more...
FDA approved LyGenesis' phase 2a trials on liver failure patients
Longevity Technology - 30-Dec-2020
Raised $11M funding which goes into trials and developing functional organsRead more...
Jim Mellon plans to take his longevity company Juvenescence public
CNBC - 29-Sep-2020
The company with $170 million private funding has invested in various life extension therapiesRead more...
Labiotech gathers feedback from European biotechs on Unity failure
Labiotech - 28-Aug-2020
General feeling that failures are bound to happen - but that their approaches can succeedRead more...
Juvenescence appoints a new CEO for its Epigenetic Division and Souvien Bio Ltd
Juvenescence - 11-Jun-2020
Goal is to develop drugs that target epigenetic mechanisms associated with neurodegenerationRead more...
Orion College ageing research receives 1 million UK pounds from Jim Mellon
Lifespan.io (LEAF) - 18-May-2020
He believes in the importance of boosting immunoresilience among elderlyRead more...
Master Investor Magazine focuses on longevity in its Autumn edition
Master Investor - 01-Nov-2019
Interesting articles and some useful investment opportunitiesRead more...
A mission to change the lives of 1 billion people
Telegraph - 23-Sep-2019
Life extension technology will be expensive, so it'll create inequalities between poor, rich peopleRead more...
Today's 50 year-olds may live another 100 years
Forbes - 26-Aug-2019
Good summary of some major investments in life extension companiesRead more...
Aging focused biotechs forms AI based joint venture
FierceBiotech - 14-Aug-2018
Groundbreaking research biotechs performs aging research together for longevityRead more...
FoxBio is developing small molecule drugs to target ageing diseases
Business Wire - 12-Jul-2018
Antoxerene partners with Juvenescence to discover drugs that clear senescent cellsRead more...
UK biotech company focused on developing anti-ageing therapies
PMLiVE - 12-Jun-2018
LyGenesis seeks to use a patient’s own lymph nodes as bioreactors to grow functioning ectopic organsRead more...
Interview with Juvenescence author Jim Mellon
Medium - 17-May-2018
Juvenescence Ltd is making investments in the future of rejuvenation and life extension technologyRead more...
Silicon Valley and rich people invest to slow down ageing and live longer
This Is Money - 17-Mar-2018
All the money in the world to fight ageing and deathRead more...
British billionaire gambles on an anti-aging upstart
Endpoints News - 26-Jul-2017
We are at an inflection point for the treatment of aging. We can generate molecules with specifi...Read more...